Rheumatoid arthritis clinical benefits from abatacept, cytokine blockers, and rituximab are all linked to modulation of memory B cell responses.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. The commonness in immune infiltration of rheumatoid arthritis and atherosclerosis: Screening for central targetsFrontiers in immunology · 2022
   Article
2. Personalized medicine in rheumatology: the paradigm of serum autoantibodies.Auto- immunity highlights · 2017
   Review
3. Persistence of Disease-Associated Anti-Citrullinated Protein Antibody-Expressing Memory B Cells in Rheumatoid Arthritis in Clinical Remission.Arthritis & rheumatology (Hoboken, N.J.) · 2017
   Article
4. [Treat to target and personalized medicine (precision medicine)].Zeitschrift fur Rheumatologie · 2016
   Review

Corrections and comments

• Comment on
  Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis.2014

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as